Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The EHA data presentations represent a significant moment for Lilly's hematology ambitions.

  60% confidence

• Lilly has a relentless commitment to pursue meaningful advancements for people living with blood disorders.

  60% confidence

• The Phase 3 BRUIN CLL-322 results address an important question for patients with relapsed or refractory CLL, demonstrating that time-limited pirtobrutinib can meaningfully improve outcomes when added to an already effective venetoclax-based regimen.

  60% confidence

• Pirtobrutinib plus venetoclax and rituximab produced positive results versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL in the Phase 3 BRUIN CLL-322 study.

  60% confidence

• AJ1-11095 is a first-in-class type II JAK2 inhibitor for patients with myelofibrosis who have been failed by a type I JAK2 inhibitor.

  60% confidence

Cited in these Via News reports

• Gilead Buys Ouro Medicines, Gives Spin-Off $500M to Build Global Inflammation Pipeline →
• Gilead and Europe's Lakefront Close $500M Ouro Deal in Cross-Atlantic Biotech Push →